Specializing in the treatment of cancer and autoimmune diseases, Regen BioPharma Inc. (OTC: RGBP) and (OTC: RGBPP) is a biotech penny stock making notable contributions to the study and treatment of cancer. Currently focused on the development of its NR2F6 therapies, RGBP a an extensive portfolio of patents and its applying for more. Despite trading at a dip, RGBP...
upon review bullish divergence can be seen when combining rsi with price action
mac d is coming to retest
candles give off sign we''ve hit the bottom
huge buy of 30k today
descending triangle spotted that may break up or down
The Barchart Technical Opinion rating is a 72% Buy with a Weakest short term outlook on maintaining the current direction.
Long term...
Long term indicators fully support a continuation of the trend.
Using RSI in combination with price action, bullish divergence had can be seen.
The 20sma has bullishly crossed the 200 sma
Maybe look for entries if a golden cross forms,
The golden cross is a technical chart pattern indicating the potential for a major rally. The golden cross appears on a chart when...
Regen Biopharma, Inc. is a biotechnology company, which focuses on the immunology and immunotherapy space. The firm engages in advancing novel technologies through pre-clinical and Phase I/ II clinical trials. It is also involved in small molecule therapies for treating cancer and autoimmune disorders. The company was founded on April 24, 2012 and is headquartered in La Mesa, CA.
OTC
